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Abstract
The road to individualized therapy goes through detecting specific targets (e.g., anti‐
gens), suitable for influence, and their selective targeting by using specially designed
molecules (e.g., antibodies). A significant advance in this area is the development of ther‐
apeutic monoclonal antibodies. This approach enables maximizing the therapeutic effect
on one hand, and reducing systemic toxicity on the other hand. In recent years, signifi‐
cant progress was made in improving their pharmacological performance – pharmacoki‐
netics (longer half-life) and pharmacodynamics properties (better efficacy because of
stronger affinity to human receptor), and safety profile (less antigenic and immunogenic
reactions). Interleukins are a diverse, multifunctional group of proteins that carry out
communication between various immune cells and control their gene expression. They
manage the intensity and magnitude of an inflammatory response, and control differen‐
tiation, proliferation, and secretion of antibodies. Therefore, interleukin network repre‐
sents an interesting pharmacological target, modulation of which using either biological
or small chemical agents could contribute to suppression of excessive activated immune
system and successfully treat the diseases that they are involved in.
Keywords: Monoclonal antibodies, pharmacological properties, pharmacokinetics, phar‐
macodynamics, cytokines, interleukins
1. Introduction
An effective immune response is possible only through the interaction of several cell types. To
coordinate this process, there are a number of mechanisms for communication between
immune cells, including a plurality of immunomodulating signaling molecules, such as
cytokines. An officially recognized definition of the cytokines does not exist. Cytokines are a
group of regulatory molecules with protein or glycoprotein structure (relatively small
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molecular mass ~10-35 kDa) that carry intercellular signals between immune system cells. The
name “cytokine” was coined to describe both – a cell, cyto, and a movement, kinos. Due to the
immense structural and functional differences between cytokines their classification is very
difficult. In natural immunity, the effector cytokines are mostly produced by mononuclear
phagocytes and therefore often called monokines. Although monokines can be elicited directly
by microbes, they can be also secreted by mononuclear phagocytes in response to antigen-
stimulated T-cells, i.e., as part of specific immunity. Most cytokines in specific immunity are
made by activated T-lymphocytes, and these molecules are often called lymphokines. T-cells
produce several cytokines that function primarily to regulate the growth and differentiation
of various lymphocytes and play important roles in the activation phase of immune response.
The major group among cytokines is the group of interleukins, which are produced by a
plurality of nuclear cells in response to various stimuli. The main functions of the interleukins
are:
• Mediating the inflammatory response.
• Involved in the Th1- and Th2-immune response.
• Lymphocyte growth and differentiation.
• Chemoattractants for lymphocytes and polymorph nuclear leukocytes.
• Play role in hematopoiesis.
• Some of them could inhibit inflammatory process (e.g., IL-10, IL-13).
Therefore, the interleukins represent a huge interest for researchers. Their role in plenty of
diseases with excessive activity of the immune system contributes to this as well. Antagonists
of the interleukins or their receptors act immunosuppressive and are successfully applied in
such disorders. The name “interleukins” was proposed by scientists in 1979 during the Second
International Lymphokine Workshop in Switzerland and comes from the prefix inter, which
means between (carrying out communication) and leukins, which determines their origin and
their action (production from and influence on leukocytes). [1] By 1978, with the introduction
of modern methods of purification of proteins, it became clear that interleukin (IL) can be
separated into two proteins – IL-1 and IL-2 – depending on cell targets and functions. By that
time, it was known that Interleukin-1, which is produced by monocytes/macrophages, was a
lymphocyte-activating factor and Interleukin-2 was a T-cell growth factor, thymocyte-
stimulating factor, and costimulator. Today it is clear that IL-2 supports the growth of natural-
killer (NK) T-cells and especially the subpopulation of NK cells known as lymphokine
activated killer (LAK) cells, which are involved in killing tumor cells. This discovery contrib‐
uted to the approval of IL-2 as a cancer therapeutic drug that is able to stimulate the recruitment
and expansion of natural killer cells in order to attack tumor cells.
Nowadays 37 different interleukins are known, the numbering of which is in order of increase
in numbers from 1 to 37. [2] Approved monoclonal antibodies affect certain members of the
family of interleukins, such as IL-1, IL-2, IL-6, IL12/23, or IL-17, the function of which is
considerably studied and proven (Tables 1 and 2).
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Interleukins Origin Biological function References
IL-1 Macrophage, Monocytes,Fibroblast, and Dendritic cells
Inflammation, fever, activation of T- and
B-cells [2, 3, 4]
IL-2 Th type 1-cells T-cell proliferation and expansion [7, 8]
IL-6 Macrophage, Monocytes, Thtype 2-cells, B-cells Inflammation, fever, activation of B-cells [14, 15]
IL-12 Macrophage, B and T-cells,Dendritic cells
Synergistic with IL-2, INF-γ, and TNF-α
production in T-cells [20, 21, 22, 23]
IL-17 Th type 17-cells Inflammation, angiogenesis [27]
IL-23 Antigen-presenting cells (APC) INF-γ production, reduce CD8+ T-cellproliferation, angiogenesis [20, 21, 22, 23]
Table 1. Some interleukins, their origin, and biological function.
MAb Molecular type Interleukin target(s) Indication(s)
Canakinumab Human IL-1β
Cryopyrin-associated periodic syndromes
(CAPS), active systemic juvenile idiopathic
arthritis (SJIA)
Basiliximab Chimeric IL-2 (CD25) Prevention of acute organ rejection
Daclizumab Humanized IL-2 (CD25) Prevention of acute organ rejection
Tocilizumab Humanized IL-6 Rheumatoid arthritis (RA)
Ustekinumab Human IL-12/23 Plaque psoriasis, psoriatic arthritis
Secukinumab Human IL-17A Plaque psoriasis
Table 2. Approved monoclonal antibodies directed against interleukins.
1.1. Therapeutic monoclonal antibodies
Therapeutic monoclonal antibodies have gained large attention over recent decades because
of their desirable features, such as high potency and safety profile. Nowadays, they are used
in almost all clinical fields, ranging from toxin and pathogen neutralization or clearance to
influence endogenous cytokine, treating cancer, and in modulation of many other diseases. [3]
The first monoclonal antibodies were generated in mice in 1975 using a hybridoma technique,
first described by Kohler and Milstein [4]. They were rewarded ten years later, in 1984, with
the Nobel Prize in Medicine for their discovery. The key feature of a monoclonal antibody is
its unique specificity. Monoclonal antibodies are monovalent antibodies that bind to the same
epitope and are produced from a single B-lymphocyte clone. This homogeneity will give rise
to the same immunological effector functions. In principle, monoclonal antibodies can be
produced in unlimited quantities, because the hybridoma cell itself survives after cryopreser‐
vation at least for decades. Monoclonal antibodies are classified according to an international
terminology (Table 3).
Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins
http://dx.doi.org/10.5772/61774
263
Prefix Target infix Origin infix Suffix
Variable -o(s)-: Bone -u-: Human -mab
-vi(r)-: Virus -o-: Mouse
-ba(c)-: Bacteria -a-: Rat
-li(m)-: Immune system -e-: Hamster
-ci(r)-: Cardiovascular System -xi-: Chimeric (e.g., mouse-human orhamster-human)
-tu(m)-: Tumor (general) -zu-: Humanized
-neu(r)-: Nervous system -axo-: Hybrid (rat-mouse
-ki(n)-: Interleukin
-mu(l)-: Musculoscelettal System
-tox(a)-: Toxine
Table 3. Classification of monoclonal antibodies according to an international terminology.
Single syllables of the name suggest the origin and therapeutic area in which they are used.
Examples: Cana-kin-u-mab – human monoclonal antibody directed against interleukins; Basi-
li-xi-mab – chimeric immunotropic monoclonal antibody, etc.
The first licensed monoclonal antibody was Orthoclone OKT3 (muromonab-CD3), which was
approved in 1986 for use in preventing kidney transplant rejection. [5] It is a monoclonal mouse
IgG2a antibody whose cognate antigen is CD3. It works by binding to ε (epsilon) – chain of
the CD3-proteins expressed on T-lymphocytes, inhibits CD3-associate effects and interrupts
T-cell receptor mediated signal transduction. However, due to significant reported side effects,
its use was limited to acute cases. [6] One of the most important adverse effects is a cascade of
systemic cytokine release that has been termed cytokine release syndrome (CRS) or cytokine
storm. CRS is associated with increased serum levels of cytokines (e.g., TNFα, IL-2, IL-6, INF-
γ) that peak between 1 and 4 h after dose, duration 12–16 h, and severity could be mild to life-
threatening. Signs and symptoms include fever, chilling, dyspnea, wheezing, chest pain and
tightness, nausea, vomiting, and diarrhea. Hypervolemic pulmonary edema, nephrotoxicity,
meningitis, and encephalopathy are possible [7].
1.2. Targeting IL-1
Although the family of interleukin-1 incorporates many members, two of them are studied
best – IL1α and IL-1β, encoded by two related but distinct IL‑1 genes – IL1A and IL1B,
respectively. The both interleukins are strongly proinflammatory molecules that modulate the
peripheral immune response during infection and inflammation [8]. These cytokines increase
the expression and activity of adhesion molecules (e.g., VCAM-1, ICAM-1, L-selectine) that
promote attraction of immunocompetent cells to the site of infection. The more potent
inflammatory cytokine is IL-1β, which has been demonstrated in numerous in vitro and in
vivo animal models [9]. Two types of IL-1 receptor are cloned with different physiological and
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pharmacological characteristics: IL-1R1 and IL-1R2, respectively [10]. There is also a natural
glycoprotein inhibitor of the receptors for IL-1, IL-1Ra (IL-1 receptor antagonist), which
modulates the effects of both cytokines by competing with them for binding sites of the
receptor, and a number of other molecules that directly regulate IL-1 activity, such as the IL-1
receptor type I (IL-1RI), the decoy receptor IL-1 receptor type II (IL-1RII), its coreceptor IL-1
receptor accessory protein (IL-1RAcP), and soluble receptor forms.
In humans, IL-1 plays a major role in bone resorption and cartilage destruction by inducing
prostaglandin E2 and proteolytic enzymes, such as matrix metalloproteinase. [11] This led to
the development of interleukin-1 inhibitors, as a possible therapeutic strategy in rheumatoid
arthritis and other chronic inflammatory diseases.
IL-1β plays a crucial role in the pathogenesis of multiple myeloma (MM) [12]. This is based on
the fact that IL-1β is the main cytokine in the bone marrow, which increases production of the
paracrine IL-6, the primary growth factor, responsible for survival and expansion of the
myeloma cells. Reducing IL-1β activity could be a possible way for slowing disease progression
and induction of the chronic disease state in patients with smoldering or indolent multiple
myeloma, as shown the results from phase II clinical trial with IL-1RA [13]. Since the receptor
antagonist – anakinra – has a short plasma half-life and the need for frequent administration,
the monoclonal antibodies would be superior options due to their longer plasma half-lives and
less frequent administration.
The role  of  IL-1β was established in  both types of  diabetes.  In  very low concentrations
(picomolar), IL-1β is able to destroy insulin-producing pancreatic β‑cells [14]. High glucose
concentrations stimulate IL‑1β production from the β‑cell itself [15], thus implicating a self-
destructive role for IL‑1β autoinflammation by the β-cell and the recruitment of immune
cells via IL‑1β‑driven chemokines [16]. The IL‑1β derives either from the β‑cell itself or from
the infiltrated blood monocytes in the islet. Caspase-1 dependent IL-1β production has been
observed  in  macrophages  available  in  human  adipose  tissues,  which  demonstrate  the
connection between obesity and type 2 diabetes [17, 18]. Improved insulin sensitivity and
decreased  insulin  resistance  have  been  shown  in  diabetic  mice,  administered  with  cas‐
pase-1 inhibitor [17].
IL-1 takes part in cardiovascular events, such as stroke, myocardial infarction, kidney failure,
liver failure, acute lung injury, each one of them with rapid loss of function. The ischemic event
in the myocardial infarction and thrombotic stroke starts with a sudden blockage of a blood
vessel by a clot formatted after atherosclerotic plaque rupture. The result of the blockage is
hypoxia (decreased oxygen supply) and death of the cells [19].
Pharmacological approaches affecting the function of IL-1 include:
• Using recombinant nonglycosylated molecule of human IL-1 receptor antagonist (IL-1RA)
produced in E.coli – Anakinra, marketed as Kiniret® (Amgen). It was introduced to the
practice in 1993 and it blocks the activity of both IL‑1α and IL‑1β. Anakinra currently
dominates the field of IL‑1 therapeutics and is the drug of choice in cryopyrin-associated
periodic syndromes (CAPS), and it is also prescribed to treat rheumatoid arthritis in patients
in whom one or more disease-modifying anti-rheumatic drugs (DMARDs) have failed.
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• Using fusion protein, consisting of the ligand-binding domains of the extracellular portions
of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein
(IL-1RAcP) linked to the Fc region of human IgG1 – Rilonacept (Arcalyst®), currently in use
to treat CAPS.
• Using human monoclonal antibody against IL-1β – Canakinumab or Gevokizumab.
• Orally active small-molecule inhibitors of IL‑1 production, such as caspase 1 inhibitors,
which are under investigation.
1.3. Pharmacological properties of canakinumab
Canakinumab (ACZ885) is a high-affinity human monoclonal anti-interleukin-1β antibody,
with molecular size ∼150 kDa, designed to bind and neutralize the activity of human IL-1β. It
is registered under trade name Ilaris® (Novartis) and is approved for treatment of cryopyrin-
associated periodic syndromes (CAPS) and active systemic juvenile idiopathic arthritis (SJIA).
The CAPS cover various progressive, hereditary inflammatory diseases caused by a mutation
of the NALP3 gene. The NALP3 protein (cryopyrin) is a component of a protein complex,
named inflammasome. The active inflammasome complex activates the enzyme caspase-1,
which cleaves pro-IL-1β to the biologically active IL-1β. NALP3 regulates IL-1β levels. If there
is a mutation, even a relatively weak stress agent such as cold is enough to stimulate the
synthesis of IL-1β [20]. After administration, canakinumab bind with high affinity to IL-1β and
form a complex – canakinumab-IL-1β. This complex is eliminated very slowly, due to its larger
size, and this leads to increasing plasma concentrations of both unbound and bound IL-1β.
Total IL-1β concentrations can therefore be used as a surrogate pharmacodynamic marker of
“drug activity” (i.e., binding of IL-1β by the antibody), as it is easily detected following
canakinumab administration [21]. From the following mechanism of action can be expected
typical pharmacokinetic properties of human IgG-type immunoglobulins like slow serum
clearance (0.174 L/day), low total volume of distribution at steady state (Vss ~ 6.0 L), and a long
elimination half-life of 26 days. Bioavailability after subcutaneous administration is 70%.
Canakinumab shows dose-dependent (linear) pharmacokinetics both given as an intravenous
infusion and as a single subcutaneous administration [21]. In clinical trials, canakinumab
achieved a complete and sustained remission in patients with CAPS and a mutation in the
NALP3 gene, regardless of phenotype and severity. The effect occurs rapidly. After a single
subcutaneous administration 97% of IL-1β-mediated symptoms (such as fever, joint and
muscle pain, skin rashes, tissue damage and inflammation) had disappeared after eight weeks.
A 90% remained symptom-free for up to one year if they received canakinumab injection in
eight-week intervals [22]. In general, the adverse effects of canakinumab are mild to moderate.
The most common adverse effects (>10% of treated patients) are reactions at the injection site,
inflammation of the upper respiratory tract or sinuses, and headache [23].
1.4. Pharmacological properties of gevokizumab
Gevokizumab (XOMA 052, XOMA Corporation, Berkeley, CA, USA) is a recombinant,
humanized IgG2 monoclonal antibody that binds to IL-1RI allosterically, reducing the
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formation of the IL-1RI:IL1RAcP signaling complex [24], which distinguishes it from other
monoclonal antibodies. The clinical significance of these differences is not known.
Gevokizumab is produced in Chinese hamster ovary cells and has shown activity on animal
models against RA, gout, and Type 2 diabetes. Additionally, in mouse models of myocardial
infarction and atherosclerosis, gevokizumab maintained left ventricular function [25] and
decreased markers of atherosclerosis [26], respectively. Gevokizumab was investigated in a
randomized, placebo-controlled, dose-escalation first-in-human study conducted in the
United States (NCT00513214) and Switzerland (NCT00541983) on patients with Type 2
diabetes. For the purposes of the study, single and multiple doses of gevokizumab were given
i.v. or s.c. to 98 patients with poor-controll diabetes, which are treated with standard anti-
diabetes therapy [27]. In this study, gevokizumab was well-tolerated. The most serious adverse
reactions were carcinomatous appendix and occlusion of carotid artery, which were not
considered to be drug-related. One insulin-dependent patient experienced episodic symptoms
of hypoglycemia, which was not considered to be related to treatment. The changes of
pharmacokinetic parameters of gevokizumab were dose-related. The mean half-life was 22–
23 days, which allows subcutaneous application once a month. After this study, XOMA started
a IIb phase study of gevokizumab in 421 Type 2 diabetic patients at multiple sites in the United
States during 2010 with metformin therapy on background (NCT01066715). The initial
endpoint of the study (change in HbA1c levels from baseline compared to placebo) was not
reached, but the development in cardiovascular diseases is ongoing. Another two studies are
exploring the effects of gevokizumab on beta islet cell function in patients with Type 1 diabetes.
Gevokizumab  is  in  phase  III  clinical  trial  in  treatment  of  both  acute  and  controlled
noninfectious uveitis  (NIU) and Behcet uveitis – EYEGUARD™ – A, B,  C [28].  Previous
results  were quite encouraging.  Seven patients received a single infusion of  0.3 mg kg−1
gevokizumab. Rapid and long-lasting clinical response was established in all patients after
the treatment with gevokizumab. Intraocular inflammation was resolved completely in 4–
21 days (median 14 days),  with a median duration of response of  49 days (range 21–97
days). One of the patients during the study was exacerbation-free. No one needed rescue
therapy during the study period [29].
There are recent reports of a novel fully human anti-IL-1β IgG1 – P2D7KK, with greater affinity
for IL-1β than canakinumab, which potently neutralizes human, mouse, and monkey (rhesus
macaque) IL-1β, and significantly reduces pathological signs of various models of animal
diseases [30]. Authors of that publication argue that in animal model of MM the new mono‐
clonal antibody showed significant protection from myeloma-induced lethality, as 70% of
P2D7KK-treated mice survived compared with 20% in the isotype group, and are hopeful that
it has potential as an anticancer therapeutic.
1.5. Targeting IL-2
Interleukin (IL)-2 is a small (15-kDa), α-helical cytokine produced primarily by recently
activated T-cells. It binds to a receptor (IL-2R) that is composed of three subunits, an α-chain
that functions only for IL-2 binding (IL-2Rα, CD 25) and the β (IL-2Rβ, CD 122) and γ (IL-2Rγ,
CD 132) subunits (Figure 1), which function to augment ligand binding and induce cellular
signaling.
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Figure 1. Structure of IL-2 receptor. A. In the absence of binding of IL-2 B. After binding to IL-2 and forming a stable
heterotrimer, which then leads to the initiation of signal transduction.
IL-2 is an essential cytokine produced mainly by CD4+ T lymphocytes for promoting the clonal
expansion of recently antigen-activated T cells [31]. Beside acting as T-lymphocyte growth
factor, it has been found that IL-2 takes part in the activation of apoptosis and the development
of regulatory T-cells and cytotoxic T lymphocytes [32]. This cytokine is of a great interest in
pharmacology because, on one hand, the activation of interleukin-2 receptor results in
stimulation of the immune system and can be used for inducing cytotoxicity on NK-resistant
tumor cells; on the other hand, its inhibition could lead to suppression of unwanted immune
responses, especially those that occur in autoimmune diseases or transplant rejection reactions.
Recombinant human interleukin-2 (rhIL-2, Aldesleukin, Proleukine®, Chiron Corporation,
Emeryville, CA) is used in clinical practice. It differs from the native IL-2 that lacks the first
amino acid (alanine) and the cysteine at position 125 is replaced by serine. In contrast to the
natural IL-2, aldesleukin is not glycosylated [33]. Aldesleukin stimulates the growth of
activated T- and B-cells as well as NK (natural killer) cells by the IL-2 receptor. It can activate
lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells. It was
approved in 1993 for treatment of metastatic renal cell cancer and later for metastatic mela‐
noma. Aldesleukin displays biphasic pharmacokinetics, with an alpha (distribution) half-life
of 13 min and a beta (terminal) half-life of 85 min. In cancer patients, the mean clearance rate
of aldesleukin is 268 ml/min. The dose of aldesleukin in metastatic renal cell carcinoma and
melanoma is 600,000 int. units/kg every 8 h for a maximum of 14 doses. Repeat after 9 days for
a total of 28 doses per course. If needed, retreatment is made 7 weeks after previous course.
The other product with IL-2 is denileukin diftitox (Ontac®, Seragen, Inc., Hopkinton, MA)
consisting of diphtheria toxin fragments A and B fused to interleukin-2. In the recurrent or
refractory cutaneous T-cell lymphoma, (CTCL), a rare slow-growing form of non-Hodgkin’s
lymphoma, in patients whose malignant cells express the CD25 component of the interleukin-2
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receptor is indicated. It interacts with high-affinity interleukin-2 receptor on the surface of
malignant cells and, via receptor-mediated endocytosis enters intracellular. Then enzymati‐
cally active fragment A portion of diphtheria toxin inhibits protein synthesis and leads to cell
death. The pharmacokinetic parameters of Denileukin diftitox include terminal half-life of 70–
80 min, Vd ~0.06 to 0.08 L/kg, and CLtot ~1–2 ml/min/kg. Clearance could be significantly
affected by the development of antibodies to denileukin diftitox, reducing mean systemic
exposure by approximately 75%. In patients with CTCL, intravenous dose of denileukin
diftitox is 9 or 18 mcg/kg/day; days 1 through 5 days every 21 days for 8 cycles.
1.6. Pharmacological properties of basiliximab and daclizumab
The chimeric monoclonal antibody basiliximab (Simulect®, Novartis, New York, NY, USA) and
humanized monoclonal antibody daclizumab (Zenapax®, Roche Pharmaceuticals, Nutley, NJ,
USA) have identical mechanisms of action, specifically bind the alpha subunit of the interleu‐
kin-2 (CD25) receptor on activated T-lymphocytes, thereby reducing IL-2-mediated T-cell
proliferation. Daclizumab was approved by the FDA in 1997 as the first humanized therapeutic
mAb, composed of 90% human and 10% murine antibody sequences with a binding affinity
of 3 nM to IL-2Ra, about one-third that of its murine parental antibody. The both antibodies
are indicated for prevention of acute organ rejection in adult and pediatric renal and liver
transplant recipients in combination with other immunosuppressive agents [34], with no
increase in opportunistic infections or adverse effects, proven to be a class of effective and
specific immunosuppressive agents. Basiliximab requires only two doses. The first dose 20 mg
should be given within 2 h prior to transplantation surgery. The recommended second dose
20 mg should be given 4 days after transplantation. Pharmacokinetic parameters of basiliximab
are: total body clearance (Cltot ~0.075 L/h), volume of distribution at steady state (Vss ~8 L),
and an elimination half-life of approximately 7,4 days [35]. Basiliximab was found to be safe
and effective when used in a maintenance regimen consisting of cyclosporine, mycophenolate
mofetil, and prednisone. [36] Although, daclizumab has a longer half-life (20 days), it is applied
more frequently than basiliximab. The standard course of treatment with daclizumab requires
administration of five doses. The first dose (1 mg/kg given intravenously over 15 min in 50–
100 mL of normal saline) should be given no more than 24 h before transplantation. The four
remaining doses should be given at intervals of 14 days [37]. Both drugs are well-tolerated,
but anaphylactic reactions can occur. The risk of incidents of lymphoproliferative disorders
and opportunistic infections is low [38]. There are many other diseases, with pathological
immune response, which are a subject to the therapy with anti-IL-2 receptor antibodies, like
multiple sclerosis, psoriasis, uveitis, etc. However, clinical trials are still ongoing.
1.7. Targeting IL-6
Interleukin-6 (IL-6) is a cytokine of approximately 26 kDa, which is synthesized by mononu‐
clear phagocytes, vascular endothelial cells, fibroblasts, and other cells in response to IL-1 and,
to a lesser extent, TNF. It exerts pleiotropic effects on many cells and plays a central role in
diverse host defense mechanisms such as the immune response, hematopoiesis, and acute-
phase reactions [39]. IL-6 is capable of stimulating the proliferation and activation of synovio‐
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cyte and osteoclasts, which leads to formation of synovial pannus. In combination with IL-1,
they increase production of matrix metalloproteinases, which induces joint and cartilage
destruction [40]. IL-6 induces the synthesis of the major mediators of the acute phase response,
such as serum C-reactive protein (CRP) and amyloid A. IL-6 high levels correlate with disease
activity and clinical manifestations of rheumatoid arthritis, systemic-onset juvenile idiopathic
arthritis (sJIA), Castleman’s disease, and systemic lupus erythematosus (SLE) [41, 42].
IL-6 transmits its signals in two pathways: binding to a membrane receptor (mIL6R or CD126)
or to its soluble form (sIL6R) (Figure 2).
Figure 2. Pleiotropic effects of IL-6.
For both pathways, IL-6 stimulation activates Janus family tyrosine kinases (JAKs), which are
associated with gp130 IL6 transducer (CD130), leading to the induction of two major signal
transduction pathways, signal transducer and activator of transcription (STAT-3) pathway and
mitogen-activated protein kinases (MAPKs) pathway [42]. Targeting and inhibiting IL-6R is a
new promising pharmacological approach leading to a significant improvement of signs and
symptoms in dysimmune diseases, such as rheumatoid arthritis (RA) or Castleman’s disease,
which was demonstrated in many clinical trials with a marked reduction in disease activity
and the acute-phase response. Lately, modulating the function of IL-6 is used in treatment of
cancers.
1.8. Pharmacological properties of tocilizumab and other newly developed monoclonal
antibodies against IL-6
Tocilizumab (TCZ, Actemra®, Chugai Pharmaceutical Co Ltd, Tokyo, Japan; now a member
of the Roche Group) is a humanized anti-IL-6 receptor antibody, licensed for the treatment of
rheumatoid arthritis (RA), polyarticular and systemic juvenile idiopathic arthritis by intrave‐
nous administration of 8 mg/kg (and no less than 4.8 mg) in combination with methotrexate
(MTX) or monotherapy [43]. The subcutaneous formulation (162 mg weekly) is now entering
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phase III trials and the preliminary data have shown comparable efficacy and safety profiles
to the established intravenous formulation [44]. Tocilizumab can simultaneously bind to both
receptors – mIL6R and sIL6R – thereby interrupting the IL-6 signal pathway but does not affect
signaling of other IL-6 family cytokines [45], and without increasing the IL-6 half-life [46].
Pharmacokinetic parameters of tocilizumab include – Vdss – 2.54–4.08 L (children) and 6.4 L
(adults), the half-life is 6.3 days, but in steady state could be increased to 16–23 days (children)
and 11–13 days (adults) [47]. Adverse events associated with the usage of tocilizumab include
increased serum cholesterol and liver enzymes (ALT, AST), infusion-related reaction and
infections (especially respiratory infection, and skin and soft tissue infections). Total choles‐
terol, low-density lipoproteins, triglycerides, and high-density lipoproteins are increased in
20–30% of patients treated with tocilizumab. The possible explanation of this effect is that IL-6
modulates lipoprotein receptor expression and lowers blood lipid levels via upregulation of
the very-low-density lipoprotein (VLDL) receptor. If tocilizumab reduces the levels of IL-6, it
will increase the levels of plasma proteins [48]. According to recent studies, this elevation of
lipids does not show apparent increase in cardiac events in a follow-up of 5 years [49]. The
most common adverse events of treatment with tocilizumab were infections (such as upper
respiratory tract infection, nasopharyngitis, skin infections, pneumonia, gastroenteritis, and
urinary tract infection, both viral and bacterial), nonsignificantly higher than the placebo group
[50, 51]. Resolution of infections such as pneumonia, herpes zoster, limb abscess, osteomyelitis,
sepsis, staphylococcal cellulitis, acute pyelonephritis, and staphylococcal polyarthritis have
improved with appropriate treatment [52].
Siltuximab (CNTO 328, Sylvant®, Janssen Biotech) is a chimeric monoclonal antibody, an
interleukin-6 (IL-6) antagonist, which is indicated for the treatment of patients with multicen‐
tric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and
human herpesvirus-8 (HHV-8) negative. It is tested in clinical trials for multiple myeloma
(MM), metastatic renal cell carcinoma (MRCC), and prostate cancer [53]. The clearance of
siltuximab in patients is 0.23 L/day, according to population pharmacokinetic analysis and
body weight is the only significant determinant for siltuximab clearance. The mean serum
terminal half-life (t ½) for siltuximab in patients after the first i.v. infusion of 11 mg/kg is 21
days (range: 14–30 days). The CYP450 enzyme activity may reach its normal levels (previously
downregulated by IL6), due to binding of bioactive IL6 by siltuximab. This may result in
increased metabolism of CYP450 substrates compared with metabolism before treatment with
siltuximab. If siltuximab is coadministered with CYP450 substrate drugs with a narrow
therapeutic range, the dose of the concomitant medication may need to be adjusted. On the
basis of the population pharmacokinetic analysis, no initial dosage adjustment is necessary for
patients with baseline mild-to-severe renal impairment (CLCr ≥ 15 mL/minute) or for patients
with baseline mild-to-moderate hepatic impairment (Child-Pugh Class A and B). Patients with
baseline severe hepatic impairment (Child-Pugh Class C) were not included in clinical trials.
Within the serum siltuximab exposure range observed following administration of 11 mg/kg
i.v. every 3 weeks, no exposure–response relationships between serum CRP and siltuximab
exposure or between durable tumor and symptomatic response rate and siltuximab exposure
were identified. Following siltuximab dosing, 0.2% (1/411) of patients tested positive for anti-
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siltuximab antibodies. Further immunogenicity analyses of the single positive sample revealed
a low titer of anti-siltuximab antibodies with nonneutralizing capabilities [54].
Sarilumab (SAR153191/REGN88) is a fully human anti-IL-6Rα monoclonal antibody that binds
membrane-bound and soluble human IL-6Rα with high affinity. It blocks cis and trans IL-6-
mediated inflammatory signaling cascade. There was no reported evidence of complement-
dependent or antibody-dependent cell-mediated cytotoxicity [55]. Sarilumab inhibits IL-6
signaling in a dose-dependent manner [56, 57]. Subcutaneous application in phase I studies in
patients with RA has shown that sarilumab is generally well-tolerated, [58, 59] and reduces
the acute-phase reactants such as C reactive protein (CRP) [60]. Sarilumab improves clinical
signs and symptoms in RA patients with moderate-to-severe disease with tolerability similar
to other IL-6 inhibitors. After completing the phase II clinical trial, the most favorable efficacy,
safety, and dosing convenience were obtained by using 150 mg and 200 mg sarilumab q2w.
Those doses will be further evaluated in phase III clinical trials [61].
Sirukumab (CNTO 136) is another human monoclonal antibody that targets only soluble IL-6
and is designed for the treatment of rheumatoid arthritis. It is currently in clinical phase III.
1.9. Modulating IL-11
Interleukin-11 is an ~20 kDa cytokine produced by bone marrow stromal cells. It stimulates
megakaryopoiesis and may prove to be of therapeutic benefit in patients with platelet
deficiencies. It also enhances the development of macrophages and perhaps other cells from
marrow precursors. Neumega (oprelvekin) is a recombinant IL-11 protein product (MW ~19
kDa) approved for prevention of severe thrombocytopenia and reducing the need for platelet
transfusions following myelosuppressive chemotherapy. The recommended dose for adults
50 mcg/kg/day once daily for ~10–21 days (until postnadir platelet count ≥50,000 cells/mcL) is
administering subcutaneously. The most serious adverse effects reported are allergic or
hypersensitivity reactions, including anaphylaxis. They may occur with the first or with
subsequent doses. Patients who developed allergic reactions need to permanently discontinue
the administration.
1.10. Targeting IL-12/23
Psoriasis is a chronic inflammatory disease of the skin, affecting 2–3% of the general population
[62]. Plaque psoriasis, the most frequent form, has skin lesions in the form of scaly, red plaques.
In psoriasis, destruction of normal immune-mediated signaling is caused by the overproduc‐
tion and immature migration of keratinocytes to the surface of the skin [63]. Initially perceived
as a skin disease, psoriasis can influence physical and mental condition of the body and lead
to the development of joint disorders (psoriatic arthritis) and depression, thus significantly
affecting the quality of life. Interleukins 12 and 23 play an important role in the formation of
plaques of psoriasis. IL-12 stimulates production of IFN-gamma and tumour necrosis factor
alpha (TNFα) and it is involved in differentiating naive T-cells into T-helper (Th)-1 cells, while
IL-23 activates IL-17-producing T-cells (Th17) (Figure 3) [64, 65].
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Figure 3. IL-12 family members.
1.11. Pharmacological properties of ustekimumab
Ustekinumab (UST, Stelara®) is an IgG1/kappa human monoclonal antibody composed of 1326
amino acid residues, with a molecular weight of approximately 148.6 kDa, directed against
the shared p40 subunit of IL-12 and IL-23, thereby preventing IL-12 and IL-23 from binding to
the receptor chain IL-12Rb1 to trigger downstream signaling pathways. It is currently ap‐
proved for treatment of plaque psoriasis and psoriatic arthritis. The pharmacokinetic proper‐
ties of ustekinumab in human population do not show any serious differences in patients with
psoriatic arthritis and those with plaque psoriasis [66]. Absolute bioavailability after subcu‐
taneous administration is approximately 57% and biological half-life is ~10–126 days. In clinical
trials, ustekinumab has improved rapidly and sustainedly the symptoms of psoriasis. Even
after one injection there was a significant improvement that persisted over the 1.5-year study
period. It achieved the primary endpoint of 75% reduction in the Psoriasis Area and Severity
Index (PASI) score in a large proportion of patients in the phase III PHOENIX trials (defined
as 75% clinical improvement of affected skin areas determined by the size, severity of erythe‐
ma, plaque thickness, and scaling) compared to 3% for placebo [67]. The effect lasted for 76
weeks after treatment with ustekinumab at more than 80% of the responders. In a randomized,
multicenter study ustekinumab was compared with etanercept in the treatment of more than
900 patients with moderate-to-severe plaque psoriasis. After 12 weeks, 55% of patients
receiving ustekinumab reached (45 mg at weeks 0 and 4) PASI-75; under etanercept (50 mg
twice a week) it was 39% [68].
1.12. Targeting IL-17
Interleukin 17 (IL-17), similarly as interferon gamma, increases the production of chemokines
in the various tissues that stimulate recruitment of monocytes and neutrophils to the site of
inflammation. It was classified as a proinflammatory cytokine stimulating the production of
IL-6 and IL-8, and the surface expression of the intracellular adhesion molecule-1 (ICAM-1) in
Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins
http://dx.doi.org/10.5772/61774
273
human fibroblasts [69]. IL-17 is produced by the recently identified T-cell subset Th17 and is
under the influence of IL-23, a cytokine belonging to the IL-12 family [70]. IL-23 is proinflam‐
matory mediator, which induces chronic inflammation through the activation of Th17 cells
and the secretion of Th17 by non-T-cells, as mentioned earlier. This pathway is essential for
production of many other mediators that are involved in chronic inflammatory responses in
autoimmune diseases. Large amounts of Th17 cells are found in blood and skin lesions of
people with psoriasis. Although many signaling pathways including that of Th17 are investi‐
gated in psoriasis, IL-17A inhibitors are able to relieve psoriatic symptoms in forms resistant
to anti-TNF agents and have higher specificity than inhibitors of IL-12 and IL-23. The combi‐
nation of IL-17A and TNF-α induces a proinflammatory signaling cascade; patients who are
refractory to anti-TNF agents may respond to therapies that target IL-17A [71]. As opposed to
the agents that target IL-12 and IL-23 (ustekinumab), inhibitors of IL-17A may induce a more
specific response.
1.13. Pharmacological properties of secukinumab, izekizumab, and brodalumab
Secukinumab (AIN-457, Cosentyx®, Novartis Pharma AG) is a fully human IgG1κ monoclonal
antibody that selectively binds and neutralizes the effects of IL-17A. It is indicated for the
treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for
phototherapy or systemic therapy. In the pivotal studies, 70% of the subjects achieved a clear
or almost clear skin. For the subjects, the antibody was injected once a week for 16 weeks. The
effect was greater than the treatment with the TNF-α inhibitor etanercept (Enbrel®) and it was
held in the majority of patients on continued therapy at one year. First improvements of the
skin image appeared after two weeks only. On average, the skin symptoms had reduced after
three weeks to half of what was achieved with etanercept after seven weeks. In addition, fewer
and milder side effects than the reference were registered. [72]
Ixekizumab is a humanized IgG4 monoclonal antibody (mAb) neutralizing IL-17A. The safety
and efficacy of ixekizumab was assessed in a phase II, double-blind, placebo-controlled trial
with 142 moderate-to-severe plaque-type psoriasis patients. Patients were randomized into
five groups administering subcutaneously 150, 75, 25, 10 mg ixekizumab or placebo, at 0, 2, 4,
8, 12, and 16 weeks [73]. The achievement of 75% reduction of Psoriasis Area and Severity
Index (PASI) after 12 weeks of treatment constituted the primary endpoint of the study
occurring in 82.1, 82.8, 76.7, 29 and 7.7% of patients treated with 150, 75, 25, 10 mg ixekizumab
or placebo, respectively. The amelioration of PASI score was significantly greater in all
ixekizumab groups compared with placebo (p < 0.001 for each comparison), with the exception
of the lowest dose (10 mg) [73]. Furthermore, a statistically significant reduction of PASI score
by at least 90% was observed in the 150 mg (71.4%), 75 mg (58.6%), and 25 mg (50.0%) groups
versus placebo 0% (p < 0.001). Regarding the safety profile, the occurrence of adverse events
including nasopharyngitis, upper respiratory infection, injection site reaction, and headache
was similar across all study groups, and no serious adverse events were reported. Phase III
studies are currently ongoing; among them are a head-to-head trial with etanercept, another
head-to-head trial with adalimumab on psoriatic arthritis, and a study evaluating ixekizumab
efficacy and safety on psoriatic arthritis patients [74].
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Brodalumab is a human mAb, which blocks IL-17RA, the receptor subunit shared by IL-17A,
IL-17F, and IL-17A/F heterodimer ligands. The antagonism of IL-17 signaling by brodalumab
was primary proven clinical, genomic, and histological in 10 patients with psoriasis after only
1 week in a phase I, proof-of-concept study [75]. Its efficacy is confirmed in recent phase II,
randomized, double-blind, placebo-controlled, dose-ranging study involving 198 patients.
They received subcutaneously brodalumab of 280 mg monthly, or 70, 140, 210 mg brodalumab
or placebo at weeks 0, 1, 2, 4, 6, 8, and 10 [76]. The monthly administration of 280 mg improved
PASI score, with 45%, while other dosages (210, 140, and 70 mg) achieved 85.9%, 86.3%, and
16% of PASI score, respectively, after 12-week study assessment. The greater frequency of
adverse effects was observed in patients receiving the high-dose regimen of brodalumab. There
were two cases of mild neutropenia (grade III) among the serious adverse events [76].
Presently, phase II trials are being conducted to assess brodalumab as a therapeutic option for
psoriatic arthritis, while its ability to treat plaque-type psoriasis has already progressed to
phase III studies. Brodalumab is currently being investigated for the treatment of psoriatic
arthritis on phase II and III trials for the treatment of plaque-type psoriasis. Of relevance, one
trial evaluates clinical to withdrawal-and-retreatment with brodalumab in psoriatic patients,
and another study compares efficacy and safety of brodalumab compared with ustekinumab
(anti-IL-12/IL-23p40 agent) and placebo [77].
1.14. Potential of pharmacokinetic and pharmacodynamics drug interactions using
monoclonal antibodies
Most of the pharmacokinetic drug–drug interactions (DDIs) of small molecules occur at the
level of modulation of activity/levels of the enzymes and/or transporters involved in their
biodegradation/bioactivation and/or disposition. Because these enzymes and/or transporters
are not involved in the elimination processes of mAbs and functional derivatives, it is believed
that potential future interactions with concomitant administration of mAbs with small
molecules are unlikely. Despite that, monoclonal antibodies are not metabolized by cyto‐
chrome enzymes (CYPs) and these are not suspected for drug interactions. However, it is
known from in vitro studies [78-82] that the increased activity of certain cytokines is capable
of reducing the activity of CYP enzymes:
• CYP1A2 levels by IFN-a, IFN-a-2b, IFN-b, IL-2 and IL-6
• CYP2C8 levels by IL-1
• CYP2C9 levels by IL-2 and IL-10
• CYP2C19 levels by IFN-a-2b, IFN-b, TNF-a, IL-2, and IL-6
• CYP2D6 levels by IFN-a-2b
• CYP2E1 levels by IFN-a-2b and IL2
• CYP3A levels by IL-1, IL-2, IL-6, and IL-10
In contrast to other cytokines, IL-4 was shown to increase the activity of CYP2E1, suggesting
that another mechanism of enzyme activity regulation could be involved [78]. The molecular
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mechanisms underlying downregulation of drug-metabolizing enzyme and transporter levels
by cytokines are not fully defined but lower gene and protein expressions have been reported
for some nuclear receptors involved in regulation of CYPs and transporters including preg‐
nane X receptor (PXR), constitutive androstane receptor (CAR), and farnesoid X activated
receptor (FXR) [83, 84]. Although in vitro systems (e.g., microsomes and hepatocytes) are
routinely employed to predict in vivo DDIs of small molecules [85], the use of in vitro systems
to predict in vivo interactions between small-molecule drugs and therapeutic proteins is still
in development. Most of the problems are caused by poor correlation and extrapolation
between in vitro and in vivo results.
Influencing the levels of expression of P-glycoprotein (P-gp), also known as multidrug
resistance protein 1 (MDR1), can also contribute to DDIs. Several studies have shown that
intestinal P-gp was inversely correlated with the inflammatory disease activity. Cytokine-
mediated downregulation of P-gp in inflamed intestine of ulcerative colitis (UC) patients was
presumably dependent on disease activity, with a possible contribution from IL-8 [86].
Presence of P-gp in the membranes of blood-brain-barrier (BBB) restricts passage of drug
molecules into the brain. Some studies show that activity of P-gp was downregulated after
short-term exposure to inflammatory mediators, whereas its activity was upregulated
following more prolonged exposure [87, 88].
Modulation of activity of CYP enzymes by monoclonal antibodies, through interactions with
ILs, can enter into interactions with drugs, which are metabolized by CYPs. Clinical studies
have shown that IL-6 inhibits function of CYP1A2, 2C9, 2C19, and CYP3A4 and the function
is normalized by anti-IL-6 receptor antibody – tocilizumab [89]. When patients taking drugs
with a narrow therapeutic index that are metabolized by these CYP enzymes, for example,
atorvastatin, calcium channel blockers, theophylline, warfarin, phenytoin, cyclosporine, or
benzodiazepines, blood levels of these drugs should be monitored and clinicians should be
alert for possible interactions. It should be taken into account that monoclonal antibodies have
long elimination half-life and the effect on CYP enzymes activity may continue after treatment
for several weeks.
Pharmacodynamic (PD) interactions using monoclonal antibodies are also possible. The basic
mechanisms that are involved include reduction in target number or target-bearing cell
number, thus affecting receptor-mediated clearance [90]. The use of pharmacodynamic
interactions to improve the pharmacological effect of monoclonal antibodies is growing [91,
92]. In nonhuman primates, paclitaxel in combination with trastuzumab resulted in a 1.5-fold
increase in trastuzumab serum concentration [93]. Similarly, paclitaxel enhances the thera‐
peutic benefit of cetuximab, possibly through inhibition of angiogenesis and the induction of
apoptosis [94]. Pharmacodynamic interactions have also been reported in other clinical and
preclinical experiments [95-97]. A combination of cetuximab (mAb-targeting epidermal
growth factor receptor, EGRF) with either gefitinib or erlotinib (EGRF tyrosine kinase inhibi‐
tors) was used to maximize EGRF signaling inhibition [98]. Synergism between these drugs
has been reported in vivo in athymic nude mice and in vitro across a variety of human cancer
cell models. Synergistic antitumor activity has been reported between a taxane compound
(BMS-275183) and cetuximab using athymic nude mice [99].
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In addition, a recently published study demonstrated in mice that coadministration of anti-
VEGF antibodies reduced the delivery of a second mAb to tumor tissues. This pharmacoki‐
netic–pharmacodynamic interaction was only observable when tumor tissue levels were
analyzed as no change in plasma pharmacokinetics was observed [100].
2. Conclusions and future directions
Interleukins represent an attractive target for pharmacological interventions to fine-tune
immune cell functions for treatment of human diseases. Discovery and development of
therapeutic monoclonal antibodies is an option for achieving these objectives. However, the
impact on these intracellular signaling molecules hides many pitfalls, as the border between
useful and harmful influence is very thin. Examples of this can be the case with humanized
monoclonal antibody directed against CD28 – TGN 1412. During the phase I clinical trial, all
six volunteers receiving the drug were hospitalized, at least four of them developed multiple
organ dysfunction, despite being administered at a supposed sub-clinical dose of 0.1 mg/kg;
approximately 500 times lower than the dose found safe in animals. [101] Another case in this
regard is the occurrence of progressive multifocal leukoencephalopathy (PML) in subjects
treated with natalizumab. [102] Therefore, it is necessary to extrapolate properly the results
obtained from preclinical studies to humans by knowing very well the pharmacological
characteristics and evaluation of the risk benefits in order to prevent future tragedies.
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